Drug intelligence / Profile preview

OC-007

Development stage: Phase 1
Modality: Prophylactic Vaccines → Vaccines & Immunotherapeutics, DNA Vaccines → Plasmid DNA → DNA Therapeutics → Nucleic Acid Therapeutics
Administration: Electroporation

Overview

OC-007 is a DNA vaccine developed as a booster dose for COVID-19. It is being evaluated for its safety and immunogenicity when delivered by in vivo electroporation (EP) as a fourth booster dose in healthy adults. The mechanism of action is as a vaccine, stimulating an immune response against SARS-CoV-2 to provide protection or enhance immunity against COVID-19. There are no FDA designations or approved indications currently associated with this product[1][2][4].

Targets

SARS-CoV-2 spike

Beyond the preview

Go deeper on OC-007.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on OC-007.

Explore the full profile